Recommendations for acceleration of vaccine development and emergency use filings for COVID-19 leveraging lessons from the novel oral polio vaccine
Abstract A new oral polio vaccine, nOPV2, has become the first vaccine to pursue a WHO Emergency Use Listing. Many lessons were learned as part of the accelerated development plan and submission, which have been categorized under the following sections: regulatory, clinical development, chemistry ma...
Guardado en:
Autores principales: | Natalie Thiel, Casey Selwyn, Georgina Murphy, Shmona Simpson, Ajoy C. Chakrabarti |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7f2e418be62c46428654dc05ae26cd14 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Vaccine Hesitancy during the Coronavirus Pandemic—Lessons from Polio
por: Lakshini Gunasekera, et al.
Publicado: (2021) -
Salk Anti-Polio Vaccine
Publicado: (2017) -
Polio, approaching eradication as a result of vaccination
por: José A. Moreno-González, et al.
Publicado: (2021) -
Mammalian expression of virus-like particles as a proof of principle for next generation polio vaccines
por: Mohammad W. Bahar, et al.
Publicado: (2021) -
Plant-made polio type 3 stabilized VLPs—a candidate synthetic polio vaccine
por: Johanna Marsian, et al.
Publicado: (2017)